PharmacoEconomics - Open

2017 - 2025

Current editor(s): Timothy Wrightson and Christopher Carswell

From Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 5, issue 4, 2021

Evidence-Based Medicine and Healthcare Quality in the Context of Information Failure: The Case of the UK Fertility Sector pp. 561-576

Minyan Zhu

gammaCore for Cluster Headaches: A NICE Medical Technologies Guidance pp. 577-586

Susan O’Connell, Megan Dale, Helen Morgan, Kimberley Carter, Rhys Morris and Grace Carolan-Rees

Inclusion of Additional Unintended Consequences in Economic Evaluation: A Systematic Review of Immunization and Tuberculosis Cost-Effectiveness Analyses pp. 587-603

Liv Solvår Nymark, Alex Miller and Anna Vassall

Criteria and Scoring Functions Used in Multi-criteria Decision Analysis and Value Frameworks for the Assessment of Rare Disease Therapies: A Systematic Literature Review pp. 605-612

Tamás Zelei, Nicholas D. Mendola, Baher Elezbawy, Bertalan Németh and Jonathan D. Campbell

Hospital Costs of Extracorporeal Membrane Oxygenation in Adults: A Systematic Review pp. 613-623

Annemieke Oude Lansink-Hartgring, Olivier van Minnen, Karin M. Vermeulen and Walter M. van den Bergh

Cost-Effectiveness Analysis of rFVIIIFc Versus Contemporary rFVIII Treatments for Patients with Severe Hemophilia A Without Inhibitors in the United States pp. 625-633

Ash Bullement, Emma S. Knowles, Pronabesh DasMahapatra, Talaha Ali and Ron Preblick

A Model-Based Economic Evaluation of Cladribine Versus Alemtuzumab, Ocrelizumab and Natalizumab for the Treatment of Relapsing-Remitting Multiple Sclerosis with High Disease Activity in Chile pp. 635-647

Manuel Antonio Espinoza, Rubén Rojas, Alessandro Zaupa and Carlos Balmaceda

Smoking Cessation Pharmacotherapy Utilization and Costs to a Medicaid Managed Care Plan pp. 649-653

Robin L. Corelli, Thanh G. Tu, Kyoung J. Lee, Drake Dinh, Kristin R. Gericke and Karen Suchanek Hudmon

Cost-Utility Analysis of Dolutegravir- Versus Efavirenz-Based Regimens as a First-Line Treatment in Adult HIV/AIDS Patients in Ethiopia pp. 655-664

Yared Belete Belay, Eskinder Eshetu Ali, Karen Y. Chung, Gebremedhin Beedemariam Gebretekle and Beate Sander

Impact of Including Carer Information in Time Trade-Off Tasks: Results from a Pilot Study pp. 665-675

David J. Mott, Iain Leslie, Koonal Shah, Jennifer Rowell and Nicolas Scheuer

Cost Effectiveness of Gemtuzumab Ozogamicin in the First-Line Treatment of Acute Myeloid Leukaemia in the UK pp. 677-691

T. Alexander Russell-Smith, James Brockbank, Carla Mamolo and Christopher Knight

Cost-Effectiveness of Peer-Educator–Delivered Lifestyle Modification for Type 2 Diabetes Prevention in a Young Healthy Population in Sri Lanka: A Trial-Based Economic Evaluation and Economic Model pp. 693-700

James Shearer, Miral Kalyani, Anastasios Mangelis, Dileep Silva, Padmal Silva, Mahen Wijesuriya and Janaka Karalliedde

Non-Price-Related Determinants of Value and Access for Novel Non-small Cell Lung Cancer Treatments: A Cross-Country Review of HTA Decision Making pp. 701-713

Jason Gordon, Angela Stainthorpe, Beverley Jones, Ian Jacob, Nadine Hertel, Jose Diaz, Yong Yuan and John Borrill

Estimation of Health-Related Utilities for 177Lu-DOTATATE in GEP-NET Patients Using Utilities Mapped from EORTC QLQ-C30 to EQ-5D-3L and QLU-C10D Utilities pp. 715-725

Ioana-Alexandra Soare, Oscar Leeuwenkamp and Louise Longworth

The Costs and Healthcare Resource Utilization Associated with Anticholinergic Burden in Long-Stay Nursing Home Residents with Overactive Bladder in the US pp. 727-736

Satabdi Chatterjee, David Walker, Tomomi Kimura and Rajender R. Aparasu

Economic Evaluation of Transperineal versus Transrectal Devices for Local Anaesthetic Prostate Biopsies pp. 737-753

Edward C. F. Wilson, Alice Wreford, Priya Tamer, Kelly Leonard, Hannah Brechka and Vincent J. Gnanapragasam

Direct and Indirect Costs of Non-surgical Treatment for Acute Tonsillitis in Children in Southeast Nigeria pp. 755-764

Maduka Donatus Ughasoro, James Onuorah Akpeh, Nneamaka Echendu, Somkene Okpala, Nneka Getrude Mgbachi, Ogochukwu Chinelo Okanya and Obinna Emmanuel Onwujekwe

Cost-Minimization Analysis of Pembrolizumab Monotherapy Versus Nivolumab in Combination with Ipilimumab as First-Line Treatment for Metastatic PD-L1-Positive Non-small Cell Lung Cancer: A US Payer Perspective pp. 765-778

Nan Qiao, Ralph Insinga, Thomas Burke and Gilberto Lopes

Volume 5, issue 3, 2021

Revision of Ireland’s Cost-Effectiveness Threshold: New State-Industry Drug Pricing Deal Should Adequately Reflect Opportunity Costs pp. 339-348

James F. O’Mahony

National Healthcare Economic Evaluation Guidelines: A Cross-Country Comparison pp. 349-364

Deepshikha Sharma, Arun Kumar Aggarwal, Laura E. Downey and Shankar Prinja

A Review of Cost-Effectiveness Studies of Pembrolizumab Regimens for the Treatment of Advanced Non-small Cell Lung Cancer pp. 365-383

Nan Qiao, Ralph Insinga, Gilberto de Lima Lopes Junior, John Cook and Martin Sénécal

High-Expenditure Disease in the EU-28: Does Drug Spend Correspond to Clinical and Economic Burden in Oncology, Autoimmune Disease and Diabetes? pp. 385-396

Wolfgang Greiner, Keyur Patel, Christina-Jane Crossman-Barnes, Troels Vingtoft Rye-Andersen, Christian Hvid and Tom Vandebrouck

Onwards and Upwards: A Systematic Survey of Economic Evaluation Methods in Oncology pp. 397-410

Graeme Ball, Mitch Levine, Lehana Thabane and Jean-Eric Tarride

State-Level Variations and Factors Associated with Adult Vaccination Coverage: A Multilevel Modeling Approach pp. 411-423

Diana Garbinsky, Shannon Hunter, Elizabeth M. La, Sara Poston and Cosmina Hogea

The Healthcare Cost Burden in Adults with High Risk for Cardiovascular Disease pp. 425-435

Dat T. Tran, Dan Palfrey and Robert Welsh

Economic Evaluation of First-Line Pertuzumab Therapy in Patients with HER2-Positive Metastatic Breast Cancer in Japan pp. 437-447

Kensuke Moriwaki, Saki Uechi, Takaaki Fujiwara, Yu Hagino and Kojiro Shimozuma

Economic Impact of Coverage Expansion for Non-invasive Prenatal Testing Through a Performance-Based Risk-Sharing Agreement pp. 449-458

Taryn A. G. Quinlan, Brock Schroeder, Sue Kwon, Jane F. Barlow, Michael S. Sherman, Heather D. Anderson, Garth Wright and R. Brett McQueen

Comparison of EQ-5D-3L with QLU-C10D in Metastatic Melanoma Using Cost-Utility Analysis pp. 459-467

Hansoo Kim, Greg Cook, Stephen Goodall and Danny Liew

Impact of Letermovir Use for Cytomegalovirus Prophylaxis on Re-Hospitalization Following Allogeneic Hematopoietic Stem Cell Transplantation: An Analysis of a Phase III Randomized Clinical Trial pp. 469-473

Yoav Golan, Yuexin Tang, Shahrul Mt-Isa, Hong Wan, Valerie Teal, Cyrus Badshah and Sanjeet Dadwal

Breathing Synchronised Hypoglossal Nerve Stimulation with Inspire for Untreated Severe Obstructive Sleep Apnoea/Hypopnoea Syndrome: A Simulated Cost-Utility Analysis from a National Health Service Perspective pp. 475-489

Deirdre B. Blissett, Joerg S. Steier, Yakubu G. Karagama and Rob S. Blissett

Cost-effectiveness of a Province-wide Quality Improvement Initiative for Reducing Potentially Inappropriate Use of Antipsychotics in Long-Term Care in British Columbia, Canada pp. 491-504

Asif Raza Khowaja, Christina Krause, Colleen Kennedy, Ben Ridout, Sarah Carriere and Craig Mitton

Psychometric Validation of the Growth Hormone Deficiency-Child Impact Measure (GHD-CIM) pp. 505-518

Meryl Brod, Michael Højby Rasmussen, Knud Vad, Suzanne Alolga, Donald M. Bushnell, Jacques Bedoin and Aristides Maniatis

Economic Analysis of Transforaminal Lumbar Interbody Fusion Surgery Utilizing a Curved Bone Removal Device pp. 519-531

John H. Peloza, Michael A. Millgram, Erel Jacobian, Daniel E. Kolsky, Richard D. Guyer, Jean-Charles Le Huec and Ely Ashkenazi

Short-Term Excess Healthcare Costs Associated with Cardiovascular Events Among Adults with Type 2 Diabetes in Israel: A Retrospective Cohort Study pp. 533-544

Cheli Melzer Cohen, Nino Hallén, Gabriel Chodick, Lotmit Bourvine, Tal Waner and Avraham Karasik

Introducing Rotavirus Vaccination in Nigeria: Economic Evaluation and Implications pp. 545-557

Charles Ebuka Okafor

Correction to: Introducing Rotavirus Vaccination in Nigeria: Economic Evaluation and Implications pp. 559-559

Charles Ebuka Okafor

Volume 5, issue 2, 2021

Value of Information Analysis: Are We There Yet? pp. 139-141

Haitham Tuffaha

Mixture Cure Models in Oncology: A Tutorial and Practical Guidance pp. 143-155

Federico Felizzi, Noman Paracha, Johannes Pöhlmann and Joshua Ray

Health Economic Evidence of Point-of-Care Testing: A Systematic Review pp. 157-173

Deon Lingervelder, Hendrik Koffijberg, Ron Kusters and Maarten J. IJzerman

Systematic Literature Review of Economic Evaluations, Costs/Resource Use, and Quality of Life in Patients with Mantle Cell Lymphoma pp. 175-186

Neerav Monga, Jamie Garside, Matthew S. Davids, Constantine Tam, Katherine Ward, Iain Fotheringham, Peter O’Donovan, Lori Parisi and Christoph Tapprich

Can Private Provision of Primary Care Contribute to the Spread of Antibiotic Resistance? A Study of Antibiotic Prescription in Sweden pp. 187-195

David Granlund and Yana V. Zykova

Minimally Invasive Sacroiliac Joint Fusion with Triangular Titanium Implants: Cost-Utility Analysis from NHS Perspective pp. 197-209

Deirdre B. Blissett, Rob S. Blissett, Matthew P. Newton Ede, Philip M. Stott, Daniel J. Cher and W. Carlton Reckling

Treatment Costs of Basal Insulin Regimens for Type 2 Diabetes Mellitus in France pp. 211-219

Bruno Detournay, Zahra Boultif, Amar Bahloul, Viviane Jeanbat and Julien Robert

The Cost Effectiveness of Mental Health Treatment in the Lifetime of Older Adults with HIV in New York City: A Markov Approach pp. 221-236

Juan J. DelaCruz, Mark Brennan-Ing, Andreas Kakolyris and Omar Martinez

An Exploration on Attribute Non-attendance Using Discrete Choice Experiment Data from the Irish EQ-5D-5L National Valuation Study pp. 237-244

Edel Doherty, Anna Hobbins, David G. T. Whitehurst and Ciaran O’Neill

Exploring Patient-Reported Costs Related to Hepatitis C on the Medical Crowdfunding Page GoFundMe® pp. 245-250

T. Joseph Mattingly, Karen Li, Arnold Ng, Tieu-Long Ton-Nu and Jennifer Owens

Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England pp. 251-260

Ben Rothwell, Christopher Kiff, Caroline Ling and Thor-Henrik Brodtkorb

Understanding Patients’ Willingness to Pay for Biphasic Insulin Aspart 30/70 in a Pen Device for Type 2 Diabetes Treatment in an Out-of-Pocket Payment Market pp. 261-273

Sreenivasa Murthy, Pankaj Aneja, Arthur Joseph Asirvatham, Lise Lotte N. Husemoen, Nicolai A. Rhee and Jothydev Kesavadev

Attributable Cost of Adult Hospitalized Pneumonia Beyond the Acute Phase pp. 275-284

Derek Weycker, Aaron Moynahan, Amanda Silvia and Reiko Sato

Next-Generation Sequencing in Clinical Practice: Is It a Cost-Saving Alternative to a Single-Gene Testing Approach? pp. 285-298

Giancarlo Pruneri, Filippo Braud, Anna Sapino, Massimo Aglietta, Andrea Vecchione, Raffaele Giusti, Caterina Marchiò, Stefania Scarpino, Anna Baggi, Giuseppe Bonetti, Jean Marie Franzini, Marco Volpe and Claudio Jommi

Treatment-Related Healthcare Costs of Metastatic Castration-Resistant Prostate Cancer in Germany: A Claims Data Study pp. 299-310

Kristine Kreis, Dirk Horenkamp-Sonntag, Udo Schneider, Jan Zeidler, Gerd Glaeske and Lothar Weissbach

The Actual Operative Costs of Liver Transplantation and Normothermic Machine Perfusion in a Canadian Setting pp. 311-318

Alexandria N. Webb, Dayne L. Izquierdo, Dean T. Eurich, A. M. James Shapiro and David L. Bigam

Disparities in the Wage-and-Salary Earnings, Determinants, and Distribution of Health Economics, Outcomes Research, and Market Access Professionals: An Exploratory Study pp. 319-329

Ioana Popovici, Manuel J. Carvajal, Patti Peeples and Silvia E. Rabionet

Cost of Revision Total Knee Replacement: A Protocol for Systematic Review and Meta-Analysis pp. 331-337

Charles Ebuka Okafor, Hong Son Nghiem, Christopher Vertullo and Joshua Byrnes

Volume 5, issue 1, 2021

Want to Improve Public Health Access? Let’s Start with the Basics: Measuring Efficiency Correctly pp. 1-2

Antony Andrews

Real-World Evidence: Bridging Gaps in Evidence to Guide Payer Decisions pp. 3-11

Melissa H. Roberts and Gary T. Ferguson

Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 13-22

Rachel Houten, Janette Greenhalgh, James Mahon, Sarah Nevitt, Sophie Beale, Angela Boland, Tosin Lambe, Yenal Dundar, Eleanor Kotas and Joanne McEntee

Productivity Loss and Associated Costs Among Employed Patients Receiving Disease-Modifying Treatment for Multiple Sclerosis pp. 23-34

Machaon Bonafede, Rina Mehta, Gilwan Kim, Ila Sruti, Marc Tian, Corey Pelletier and Neil Goldfarb

Economic Burden of Chronic Obstructive Pulmonary Disease Patients in Malaysia: A Longitudinal Study pp. 35-44

Anees ur Rehman, Mohamed Azmi Ahmad Hassali, Sohail Ayaz Muhammad, Sadia Shakeel, Ong Siew Chin, Irfhan Ali Bin Hyder Ali, Jaya Muneswarao and Rabia Hussain

Fall/Fracture-Related Healthcare Costs and Their Association with Cumulative Anticholinergic Burden in People with Overactive Bladder pp. 45-55

Greta Lozano-Ortega, Carol R. Schermer, David R. Walker, Shelagh M. Szabo, Basia Rogula, Alison M. Deighton, Katherine L. Gooch and Noll L. Campbell

Investigation of Factors Considered by Health Technology Assessment Agencies in Eight Countries pp. 57-69

Akira Yuasa, Naohiro Yonemoto, Sven Demiya, Chihiro Foellscher and Shunya Ikeda

Costs of Respiratory Syncytial Virus Hospitalizations in Colombia pp. 71-76

Jefferson Antonio Buendía and Diana Guerrero Patiño

The Value of a New Diagnostic Test for Prostate Cancer: A Cost-Utility Analysis in Early Stage of Development pp. 77-88

Adam Fridhammar, Ulrika Axelsson, Ulf Persson, Anders Bjartell and Carl A. K. Borrebaeck

Healthcare Utilization and Cost Burden of Porphyria in Commercially Insured Adults in the United States pp. 89-100

Mohamed I. Elsaid, You Li, Carolyn Catalano, Carlos D. Minacapelli, Kapil Gupta and Vinod K. Rustgi

Do Rural Residents in China Understand EQ-5D-5L as Intended? Evidence From a Qualitative Study pp. 101-109

Fan Yang, Shan Jiang, Xiao-ning He, Hong-chao Li, Hong-yan Wu, Tian-tian Zhang and Jing Wu

Costs and Extra Length of Stay because of Neonatal Bloodstream Infection at a Teaching Hospital in Ghana pp. 111-120

Ama Fenny, Evans Otieku, Kwaku Appiah-Korang Labi, Felix Ankomah Asante and Ulrika Enemark

Trends in Drug Costs and Overall Survival in Patients with Metastatic Non-small Cell Lung Cancer in The Netherlands Diagnosed from 2008 Through 2014 pp. 121-127

Christine M. Cramer- van der Welle, Bas J. M. Peters, Maarten J. Deenen, Franz M. N. H. Schramel and Ewoudt M. W. Garde

Hospital Length of Stay for Patients with Severe COVID-19: Implications for Remdesivir’s Value pp. 129-131

Michaela R. Anderson, Peter B. Bach and Matthew R. Baldwin

Gaining Patient Input on Naming a Novel Patient-Reported Outcome Instrument in Chronic Weight Management pp. 133-137

Heather Rozjabek, John Fastenau, Samara Bennett and Lydia Min-Joo Lee